pimobendan has been researched along with colforsin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujimoto, S; Matsuda, T | 1 |
| Matsumori, A; Nunokawa, Y; Sasayama, S | 1 |
2 other study(ies) available for pimobendan and colforsin
| Article | Year |
|---|---|
Effects of pimobendan, a cardiotonic and vasodilating agent with phosphodiesterase inhibiting properties, on isolated arteries and veins of rats.
Topics: 1-Methyl-3-isobutylxanthine; Aminophylline; Animals; Arteries; Cardiotonic Agents; Colforsin; Drug Interactions; In Vitro Techniques; Isoproterenol; Male; Muscle Contraction; Muscle Relaxation; Muscle, Smooth, Vascular; Phosphodiesterase Inhibitors; Pyridazines; Rats; Rats, Inbred Strains; Vasodilator Agents; Veins | 1990 |
Pimobendan inhibits the activation of transcription factor NF-kappaB: a mechanism which explains its inhibition of cytokine production and inducible nitric oxide synthase.
Topics: Amrinone; Animals; Cardiotonic Agents; Colforsin; Cytokines; Humans; Interleukin-1; Luciferases; Macrophages; Mice; NF-kappa B; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Phosphodiesterase Inhibitors; Pyrazines; Pyridazines; Quinolines; Tetradecanoylphorbol Acetate; Transfection; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2000 |